Table 3.
Factors associated with major comorbidities in RA patients in multivariate logistic regression analyses
| CVD | Fragility fracture | Malignancy | ||||
|---|---|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | |
| Female | 0.70 (0.53–0.92) | 0.01* | 2.58 (1.59–4.18) | <0.01* | 1.26 (0.69–2.28) | 0.45 |
| Age, y | 1.09 (1.07–1.10) | <0.01* | 1.05 (1.04–1.06) | <0.01* | 1.05 (1.03–1.07) | <0.01* |
| RA duration | ||||||
| <5 years | 1 (Ref) | NA | 1 (Ref) | NA | 1 (Ref) | NA |
| ≥5 years | 1.33 (1.03–1.72) | 0.03* | 1.95 (1.44–2.63) | <0.01* | 0.97 (0.61–1.56) | 0.91 |
| RF/CCP+ | 1.30 (0.90–.88) | 0.17 | 1.31 (0.86–2.00) | 0.22 | 1.95 (0.89–4.27) | 0.10 |
| DAS28 | 0.97 (0.90–1.05) | 0.48 | 1.04 (0.95–1.13) | 0.44 | 1.03 (0.89–1.19) | 0.70 |
| GC ever | 1.11 (0.86–1.44) | 0.42 | 1.05 (0.78–1.40) | 0.75 | 0.61 (0.37–1.00) | 0.05 |
| MTX ever | 0.77 (0.60–1.00) | 0.05* | 0.96 (0.72–1.28) | 0.78 | 0.57 (0.35–0.91) | 0.02* |
| bDMARDs | 1.04 (0.64–1.69) | 0.86 | 1.79 (1.16–2.76) | <0.01* | 0.15 (0.02–1.07) | 0.06 |
CVD cardiovascular disease, OR odds ratio, CI confidence interval, RA rheumatoid arthritis, NA not applicable, RF rheumatoid factor, CCP anti-citrullinated protein antibody, DAS28 disease activity score 28, GC glucocorticoid, MTX methotrexate
* P < 0.05